seed
Stage
1
Investors
About
Siren Biotechnology develops AAV-based gene therapies to enable safe, durable in vivo expression of cytokine immunotherapies.
Explore Siren Biotechnology's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.